Theralase Technologies Inc develops pulsed laser technology for healthcare applications.In November 2022, Theralase Technologies Inc granted an aggregate of 7,860,000 stock options to directors, officers, employees, and advisory board members pursuant to the company’s stock option plan for CDN$0.25 per share.In September 2022, Theralase Technologies Inc closed a non-brokered private placement offering of 10,000,000 units at $0.25 per Unit raising $2,500,000,. later that month, Theralase Technologies Inc had commenced a non-brokered $CAN 2.5 M follow-on private placement equity financing.In August 2019, Theralase closed a public offering of 57,500,000 units at a price of CAD 0.30 (US $0.22) per unit for gross proceeds of CAD 17,250,000 (US $12,974,600). Each unit consisted of one common share of the company and one common share purchase warrant with each warrant entitled the holder to purchase one common share at an exercise price of CAD 0.35 (US $0.26) per share unt